Explore

Trendline Trendline
D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types
Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Trendline Trendline
Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases

Amylyx Pharmaceuticals to Announce Q1 2026 Financial Results Amid Strategic Focus on Neurodegenerative Diseases
Trendline Trendline
Revolution Medicines Challenges Erasca Over Pancreatic Cancer Drug Patent Infringement

Revolution Medicines Challenges Erasca Over Pancreatic Cancer Drug Patent Infringement

Revolution Medicines Challenges Erasca Over Pancreatic Cancer Drug Patent Infringement
Trendline Trendline
Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026
Trendline Trendline
Sapient Unveils Tumor Protein Mapping Platform to Enhance Drug Development

Sapient Unveils Tumor Protein Mapping Platform to Enhance Drug Development

Sapient Unveils Tumor Protein Mapping Platform to Enhance Drug Development
Trendline Trendline
Sapient Introduces Tumor Protein Mapping Platform to Enhance Cancer Treatment Insights

Sapient Introduces Tumor Protein Mapping Platform to Enhance Cancer Treatment Insights

Sapient Introduces Tumor Protein Mapping Platform to Enhance Cancer Treatment Insights
Trendline Trendline
AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment

AstraZeneca Exercises Option to License Pinetree Therapeutics' EGFR Degrader Program, Triggering $25M Payment
Trendline Trendline
AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal

AbbVie Secures Option to Acquire Kestrel Therapeutics for $1.45 Billion in KRAS Inhibitor Deal
Trendline Trendline
CatalYm Appoints Christian S. Schade as Chairman Amid Clinical Advancements

CatalYm Appoints Christian S. Schade as Chairman Amid Clinical Advancements

CatalYm Appoints Christian S. Schade as Chairman Amid Clinical Advancements
Trendline Trendline
Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility

Soligenix Halts Phase 3 Trial of HyBryte for Cutaneous T-Cell Lymphoma Due to Futility
Trendline Trendline
Janux Therapeutics Halts Development of JANX008 Due to Insufficient Clinical Activity

Janux Therapeutics Halts Development of JANX008 Due to Insufficient Clinical Activity

Janux Therapeutics Halts Development of JANX008 Due to Insufficient Clinical Activity